3 terminated. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
| Phase 1 | 2 | Terminated 2 |
Follow SCLC: new trials by email Literature Review of SCLC trials Research Report on SCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer Nivatrotamab - SCLC | Phase 1 / Phase 2 | Terminated | Y-mAbs Therapeutics | 3 | 2021-08-17 | 2023-08-14 |
| A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations Lucitanib - Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer | Phase 2 | Terminated | Clovis Oncology, Inc. | 18 | 2014-04-01 | 2019-07-29 |
| A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy pemetrexed, cisplatin, radiation - Small Cell Lung Cancer, Carcinoma, Small Cell | Phase 1 / Phase 2 | Terminated | Eli Lilly and Company | 9 | 2007-02-01 | 2009-10-28 |
Small Cell Lung Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Small Cell (1) · Lung Neoplasms (1)
Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Carcinoma (1) · Lung Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
Cisplatin (1) · E-3810 (1) · Pemetrexed (1) · Radiation (1)
Clovis Oncology, Inc. (1) · Eli Lilly and Company (1) · Y-mAbs Therapeutics (1)
United States (2) · Belgium (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1)